Comment: patient-specific factors predictive of warfarin dosage requirements.
Lindh
Jonatan D
JD
D000925:Anticoagulants / Q000008:administration & dosage* / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D044383:Black People / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009154:Mutation; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D014859:Warfarin / Q000008:administration & dosage* / Q000378:metabolism; D044465:White People / Q000235:genetics; D001741:Black or African American
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases